Occam Recruits David Moller as Chief Scientific Officer of Variant Bio
Variant Bio, a genomics-driven drug discovery company backed by Lux Capital, General Catalyst, Alta Partners, SoftBank, and Casdin Capital, announced David Moller, MD as Chief Scientific Officer.
In Moller, Variant captures a broadly gauged and versatile drug discovery and development leader with over two decades of experience presiding over R&D in both big pharma and biotech, including Eli Lilly and Merck. He brings with him a deep understanding of and facility for transmuting complex genetic insights into innovative therapeutic programs, a knowledge that will doubtlessly enable Variant to deliver on its substantial potential as a transformative genomics-based drug discovery and development organization.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.